Jeffrey A. Lieberman
About
In The Last Decade
Jeffrey A. Lieberman
591 papers receiving 51.7k citations
Hit Papers
Peers
Comparison fields: 5 of 200
- Psychiatry and Mental health 34.0k
- Cognitive Neuroscience 9.1k
- Clinical Psychology 8.8k
- Cellular and Molecular Neuroscience 8.6k
- Philosophy 7.1k
Countries citing papers authored by Jeffrey A. Lieberman
This map shows the geographic impact of Jeffrey A. Lieberman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Lieberman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Lieberman more than expected).
Fields of papers citing papers by Jeffrey A. Lieberman
This network shows the impact of papers produced by Jeffrey A. Lieberman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Lieberman. The network helps show where Jeffrey A. Lieberman may publish in the future.
Co-authorship network of co-authors of Jeffrey A. Lieberman
This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey A. Lieberman. A scholar is included among the top collaborators of Jeffrey A. Lieberman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey A. Lieberman. Jeffrey A. Lieberman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Title | Journal | Authors | Indexed citations |
|---|---|---|---|---|
| 1 | The neurobiology of duration of untreated psychosis: a comprehensive review | Molecular Psychiatry | Anthony W. Zoghbi, Jeffrey A. Lieberman et al. | 18 |
| 2 | High-impact rare genetic variants in severe schizophrenia | Proceedings of the National Academy of Sciences | Anthony W. Zoghbi, Ryan S. Dhindsa et al. | 33 |
| 3 | Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers | Neuropsychopharmacology | Joshua T. Kantrowitz, Jack Grinband et al. | 35 |
| 4 | Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine | The Pharmacogenomics Journal | François Girardin, Antoine Poncet et al. | 29 |
| 5 | Pharmacological Treatments for Schizophrenia | Oxford University Press eBooks | Atheir I. Abbas, Jeffrey A. Lieberman | 4 |
| 6 | Anatomical Abnormalities in Gray and White Matter of the Cortical Surface in Persons with Schizophrenia | PLoS ONE | Tiziano Colibazzi, Bruce E. Wexler et al. | 20 |
| 7 | Association study of GRIK1 gene polymorphisms in schizophrenia: case–control and family‐based studies | Human Psychopharmacology Clinical and Experimental | Yuko Hirata, Clement C. Zai et al. | 14 |
| 8 | Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia | Neuropsychopharmacology | Brian P. Marx, Richard S.E. Keefe et al. | 160 |
| 9 | Presynaptic Regulation of Dopamine Transmission in Schizophrenia | Schizophrenia Bulletin | Gholson J. Lyon, Anissa Abi‐Dargham et al. | 51 |
| 10 | Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol (American Journal of Psychiatry (2003) 160, (1396-1404)) | American Journal of Psychiatry | Jeffrey A. Lieberman, G.D. Tollefson et al. | 12 |
| 11 | Science and Recovery in Schizophrenia | Psychiatric Services | Jeffrey A. Lieberman, Robert E. Drake et al. | 112 |
| 12 | The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia | Neuroscience Letters | Daniel J. Müller, Tim Klempan et al. | 77 |
| 13 | Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association | Journal of Clinical Psychopharmacology | Pál Czobor, Jan Volavka et al. | 147 |
| 14 | Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. | PubMed | Vincenzo S. Basile, Mario Masellis et al. | 170 |
| 15 | Comprehensive care of schizophrenia : a textbook of clinical management | Jeffrey A. Lieberman, Robin Murray | 32 | |
| 16 | Novel histamine H1 gene polymorphism and clozapine-induced weight gain | American Journal of Medical Genetics Part B Neuropsychiatric Genetics | Vincenzo S. Basile, Mario Masellis et al. | 2 |
| 17 | Psychiatry : behavioral science and clinical essentials | Jerald Kay, Allan Tasman et al. | 3 | |
| 18 | Ethics in psychiatric research : a resource manual for human subjects protection | DigitalGeorgetown (Georgetown University Library) | Harold Alan Pincus, Jeffrey A. Lieberman et al. | 32 |
| 19 | Pocket companion to accompany psychiatry | Allan Tasman, Jeffrey A. Lieberman et al. | 1 | |
| 20 | The moral imperatives of medical research in human subjects. | PubMed | Jeffrey A. Lieberman et al. | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.